Chinese expert consensus on antithrombotic management of high‐risk elderly patients with chronic coronary syndrome

Figures

• 

  FIGURE 1. Antithrombotic treatment process in elderly high‐risk CCS patients. 2 , 10 bid, twice daily; CAD, coronary artery disease; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; DPI, dual pathway inhibition.

• 

  FIGURE 2. Perioperative DAPT management in elderly CCS patients undergoing noncardiac surgery. 6 , 26 GPI, intravenous platelet membrane glycoprotein IIb/IIIa receptor antagonist. aSurgeries with very high bleeding risk such as intracranial surgery, transurethral prostatectomy, posterior chamber surgery, etc.

• 

  FIGURE 3. Antithrombotic strategies for CCS patients with acute VTE without history of ACS but with history of PCI. 9 ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug‐eluting stent; PCI, percutaneous coronary intervention; VTE, venous thromboembolism; *Aspirin 75–100 mg/day (triple therapy) may be continued for up to 30 days if the risk of thrombosis is high and the risk of bleeding is low; #A small proportion of patients with high thrombotic risk and low bleeding risk may consider to continue single antiplatelet therapy + oral anticoagulant (OAC) therapy after completing standard course of antiplatelet therapy.

• 

  FIGURE 4. Antithrombotic strategies for patients with acute VTE and history of ACS. 9 ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; VTE, venous thromboembolism; *Aspirin 75–100 mg/day (triple therapy) may be continued for up to 30 days if the risk of thrombosis is high and the risk of bleeding is low; #A small proportion of patients with high thrombotic risk and low bleeding risk may be considered to continue single antiplatelet therapy + oral anticoagulant (OAC) therapy after completing standard course of antiplatelet therapy.

• 

  FIGURE 5. Management of bleeding associated with antiplatelet therapy. 78 DAPT is dual antiplatelet therapy; SAPT is single antiplatelet therapy.

• 

  FIGURE 6. Management of bleeding associated with anticoagulant drug 6 , 27 , 77 , 79 , 80 , 81